اگلا

آٹو پلے

Challenges with measurable residual disease (MRD) assessment in acute myeloid leukemia (AML)

3 مناظر • 06/27/23
بانٹیں
ایمبیڈ
administrator
administrator
سبسکرائبرز
0

Gert J. Ossenkoppele, MD, PhD of VU University Medical Center, Amsterdam, Netherlands discusses the challenges of measurable residual disease (MRD) assessment in acute myeloid leukemia (AML). Prof. Ossenkoppele explains that a lot of experience is needed to perform a MRD assessment, i.e. experienced labs need to perform the tests. The European Leukemia Net is working on recommendations and guidelines on how to apply molecular MRD and flow cytometric MRD in order to harmonize the process.
Recorded at the International Symposium on Acute Leukemias (ISAL) 2017 in Munich, Germany.

مزید دکھائیں
0 تبصرے sort ترتیب دیں
فیس بک کے تبصرے

اگلا

آٹو پلے